--We based our opinion of AEGON's primary servicing operation on the company's long, successful track record servicing multifamily/commercial real estate loans primarily originated for life insurance companies, experienced management team, good leverage of technology, and sound control environment.
*Comments on order regarding permanent injunction against Merz Pharmaceuticals. *Order restricts Merz Pharmaceuticals' ability to sell& solicit purchases of. Xeomin to remain in place until November 1,2012.
--We have reviewed Saecure 8 NHG and Saecure 9 as part of our surveillance review cycle. --Arrears levels are low and the level of credit enhancement has increased for all classes of notes in both transactions, due to deleveraging. Standard& Poor's Ratings Services today affirmed its credit ratings on all classes notes in Saecure 8 NHG B.V. and Saecure 9 B.V..
Cramer's analysis on Allergan shows that it's a high-quality stock that can be bought into weakness.
David Pyott, Allergan chairman/CEO, discusses the company's earnings, and products in the big pharma pipeline, with Mad Money's Jim Cramer.
Mad Money host Jim Cramer explains why Allergan isn't about to fall off a patent cliff like so many other big pharma companies. David Pyott, Allergan chairman, president & CEO weighs in on the company's earnings.
Making a case for lap-band surgery and discussing the benefits to patients and insurance companies, with David Pyott, Allergan CEO.
David Pyott, Allergan chairman & CEO, discusses earnings and the aesthetics business, including Botox.